TET2 and PARP inhibitors: a replication-gap vulnerability

TET2 and PARP inhibitors are connected by an unusual defect in DNA replication. When TET2-deficient cells were exposed to olaparib, their replication tracts became longer, yet the cells accumulated more DNA damage. Replication appeared to keep moving forward while leaving unfinished DNA behind.

TET2 is best known as an enzyme that helps regulate chemical modifications of DNA. Mutations in the gene are common in age-related clonal hematopoiesis and in several myeloid malignancies. Previous work had already suggested that loss of TET2, unlike loss of another frequently mutated epigenetic regulator, DNMT3A, can make cells unusually sensitive to PARP inhibitors. The new Nature Communications study investigates why.

Longer replication does not mean better replication

The researchers compared cells with functional TET2 with cells in which TET2 activity had been lost. They focused on replication forks, the moving structures where the DNA double helix is opened and copied.

After treatment with the PARP inhibitor olaparib, TET2-deficient cells produced longer replication tracts. Taken alone, that result might look like more efficient DNA synthesis. But the same cells also accumulated more DNA breaks.

The clue came from examining newly replicated DNA. Behind the advancing replication machinery, the researchers found single-stranded DNA gaps: stretches where one of the newly synthesized strands had not been completed.

PRIMPOL was important for producing this phenotype. This enzyme allows replication to restart downstream of a lesion or another obstacle. Instead of waiting for the problem to be repaired, the cell can resume DNA synthesis farther along the template. The chromosome continues to be copied, but a gap is left behind.

Reducing PRIMPOL diminished the characteristic gap accumulation seen in cells lacking TET2.

From altered DNA chemistry to a replication defect

The study then connected these gaps to TET2's biochemical role.

TET-family enzymes oxidize modified DNA bases and help shape the methylation landscape of the genome. Loss of TET2 disturbed this balance and was accompanied by an increase in 5-hydroxymethyluracil, or 5hmU.

That modification can be recognized by the DNA repair enzyme SMUG1. When SMUG1 removes the altered base, the DNA backbone remains but the base itself is missing. The result is an abasic site: a position in the DNA molecule with no informational letter attached.

Using a modified DNA-fiber assay, the researchers detected these sites in the relevant replication tracts. Their model is that TET2 loss changes the spectrum of DNA modifications, SMUG1 processing generates abasic sites, and PRIMPOL allows replication to restart beyond these obstacles. The price of that restart is a collection of single-stranded gaps left in newly replicated DNA.

A CRISPR screen added another repair enzyme, APE1, to the picture. APE1 cleaves DNA at abasic sites, and its genetic relationship with PARP-inhibitor sensitivity in TET2-deficient cells led the authors to propose that some of these lesions and gaps are ultimately converted into DNA breaks.

The complete sequence should therefore be treated as a mechanistic model rather than as a single fully proven linear pathway. Several individual steps are supported experimentally, while the final connection between them is the authors' interpretation of the combined data.

The phenotype also depended on the catalytic activity of TET2. Manipulating the related enzymes TET1 and TET3 altered the effect as well, strengthening the link between abnormal DNA-base chemistry and the replication defect rather than simply the physical absence of TET2 protein.

Why PARP inhibition exposes the weakness

PARP proteins help cells manage DNA damage. PARP inhibitors are already used in oncology, particularly in tumors carrying certain defects in DNA-repair pathways.

The vulnerability created by TET2 loss appears to be different. These cells can continue replicating past problematic sites, but they accumulate single-stranded gaps in the process. Under PARP inhibition, that hidden instability is more readily converted into DNA breaks and becomes increasingly toxic to the cell.

The authors also tested primary bone-marrow samples from patients with myeloid malignancies. Samples carrying TET2 mutations showed greater responsiveness to PARP inhibition, suggesting that TET2 status could potentially serve as a biomarker of drug sensitivity.

This was not a clinical trial. The patient material was tested experimentally outside the body, so the study does not establish olaparib or another PARP inhibitor as an effective treatment for patients with TET2-mutant myeloid disease.

What the work does establish is a more direct connection between an epigenetic mutation and the physical mechanics of DNA replication. Losing TET2 does more than alter regulatory marks across the genome. By changing DNA chemistry, it can leave unfinished stretches behind the replication fork — and those gaps may become a drug-sensitive weakness.